Ultromics Raises $55M in Series C to Revolutionize AI-Powered Heart Failure Diagnosis with EchoGo®

Ultromics is thrilled to announce that it has raised $55,000,000 in its latest funding round—a robust vote of confidence in its groundbreaking approach to heart failure detection. As pioneers in precision heart failure diagnostics, Ultromics is leading a transformative shift in cardiac care with its innovative platform, EchoGo®. This state-of-the-art tool leverages artificial intelligence coupled with advanced cardiac ultrasound imaging to deliver highly precise, efficient, and accurate assessments. By harnessing the power of the largest known heart disease dataset in echocardiography, EchoGo® empowers clinicians with critical insights, supporting timely diagnoses and early intervention strategies—particularly for challenging conditions like HFpEF. The new capital will be instrumental in accelerating the further development of diagnostic tools aimed at halting the progression of heart failure, ensuring that patients receive life-changing care sooner. In addition, the strategic partnerships with renowned institutions and industry leaders such as the Mayo Clinic, Johnson & Johnson, and Pfizer further reinforce Ultromics’ commitment to innovation and excellence. These collaborations not only fuel clinical advancements but also broaden the reach of cutting-edge research in cardiac diagnostics, setting a new benchmark in the fight against heart failure. As Ultromics embarks on this exciting next chapter, the fresh funding will enable the company to expand its efforts, scale its technology, and deliver on its promise to revolutionize heart failure diagnosis worldwide. To learn more about Ultromics' innovative journey and stay updated on future developments, visit their website and follow them on X and LinkedIn.